Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
Leyden Labs reports first human data for intranasal flu prevention antibody
Latest NewsLeyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies.
Pentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way for radiotherapeutics
Latest NewsPentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.
PharosAI partners with 10x Genomics on spatial cancer data backed by £18.9 million
Latest NewsPharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts Health NHS Trust, has partnered with 10x Genomics to generate large-scale multimodal cancer datasets from archived NHS tumor samples using 10x’s Xenium spatial biology platform.
Cereno widens clinical program as competition heats up in lung disease
Latest NewsSwedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases.
Poxel takes first step in recovery plan with €5 million equity line
Latest NewsFrench biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent the past year under financial pressure, received approval from the Commercial Court of Lyon last week to restructure its debt and continue operations.
Sartorius returns to a path of profitable growth in 2025
Latest NewsThe Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant exchange rates to around EUR 3.54 billion, while the operating EBITDA margin rose by 1.7 percentage points to 29.7%.
Kahimmune launches and secures exclusive license for dark-genome cancer vaccine platform
Latest NewsNewly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
Origami and Ipsen join forces on protein degradation in neuroscience
Latest NewsFrench biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen’s early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization
Sanofi ends 2025 on a high, but trims R&D priorities
Latest NewsParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.
CDMOs dominate the headlines – and Lonza delivers a clear message of strength
Latest NewsCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.